MILFORD, Mass., April 13, 2015
/PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of viral infections, today announced two poster presentations
on SB 9200, its lead drug candidate for the treatment of Hepatitis B
Virus (HBV) and Hepatitis C Virus (HCV) infections, at The International
Liver Congress™ 2015, 50th annual meeting of the European Association for the Study of the Liver (EASL), taking place April 22-26, in Vienna, Austria.
"We
are very pleased to have been selected to present our HBV preclinical
data and HCV Phase I data at the upcoming EASL meeting," said
Radhakrishnan (Kris) Iyer, Ph.D., Chief Scientific Officer of Spring Bank.
"This congress affords us the opportunity to highlight our drug
development programs in two difficult-to-treat viral infections to the
worldwide medical and scientific communities."
Details of Spring Bank's presentations are below:
Poster Presentation
Title:
Antiviral Efficacy and Induction of Host Immune Responses with SB 9200,
an Oral Prodrug of the Dinucleotide SB 9000, in the Woodchuck Model of
Chronic Hepatitis B Virus (HBV) Infection
Date and Time: Saturday, April 25, 2015, 12:30 pm – 1:00 pm CEST
Location: Hall B ePoster Area
Abstract Number: P0636
Session Info: Viral hepatitis: Hepatitis B & D – c. Clinical (Therapy, new compounds, resistance)
An oral presentation of the poster will also be made by Dr. Stephan Menne, Research Associate Professor at the Department of Microbiology & Immunology, Georgetown University Medical Center
Date and Time: Saturday, April 25, 2015, 12:30 pm – 1:00 pm CEST
Location: Hall B ePoster Area
ePoster screen: C-01
Late Breaker
Title:
SB 9200, A Novel Immunomodulator for Patients with Viral Hepatitis:
Phase 1 MAD Study in patients with Hepatitis C Virus (HCV) Infection
Date and Time: Saturday, April 25, 2015, 3:30 pm – 4:00 pm CEST
Location: Hall B ePoster Area
About European Association for the Study of the Liver (EASL)
Since
1966, when the association was founded, EASL has continued to grow from
a small organisation that played host to 70 participants at its first
meeting, to becoming the leading liver association in
Europe.
EASL attracts the foremost hepatology experts as members and has an
impressive track record in promoting research in liver disease,
supporting wider education, and promoting changes in European liver
policies. For more information about EASL, please visit
https://ilc-congress.eu/.
About SB 9200
SB 9200, derived from Spring Bank's
proprietary Small Molecule Nucleic Acid Hybrid (SMNH) technology
platform, is a novel anti-viral agent that uniquely acts by modulating
the host immune response to viral infections through activation of the
intracellular sentinel proteins RIG-I and NOD2. SB 9200 is being
developed for the treatment of chronic hepatitis B and C and other viral
infections.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical stage biopharmaceutical company. Based on its proprietary SMNH chemistry platform, Spring Bank
is developing a pipeline of products representing a new class of
pharmaceuticals with a wide range of applications. These rationally
designed molecules combine the selectivity of naturally occurring
nucleotides with the drug-like properties of classical pharmaceuticals.
The SMNHs have the properties of oral delivery, good pharmacokinetic
profile, low side effects and ease of manufacture. The Company's most
advanced clinical candidate, SB 9200, is a potential breakthrough drug
for the treatment for HBV, HCV and other viral diseases. SB 9200 has a
novel mechanism of action that involves modulation of the host immune
response in the presence of viral infection.
Labels: EASL 2015, SB 9200, Spring Bank